Methods: In vitro activities of ceftaroline and comparative drugs were determined against clinically significant isolates obtained from patients with proven bacterial infections. Susceptibility testing was performed using E-test and semi-automated VITEK-2 methods. Data were analyzed according to the interpretative criteria recommended by the Clinical and Laboratory Standards Institute (CLSI).
Results: A total of 556 isolates were tested. Compared with other cephalosporins such as cefepime, cefotaxime, ceftazidime and ceftriaxone, ceftaroline demonstrated excellent activities (MIC90, ≤0.5µg/ml) against Escherichia coli (93.8% were susceptible), Klebsiella pneumoniae (92% were susceptible), Proteus mirabilis (91.7% susceptible), Salmonella spp. (100% susceptible) and Haemophilus influenzae (100% susceptible). It had poor potency (MIC90, >32µg/ml) against Acinetobacter baumannii and Pseudomonas aeruginosa. When matched with the comparative cephalosporins, ceftaroline demonstrated the greatest activity against methicillin-susceptible Staphylococcus aureus (MSSA), with a MIC90 of 0.5µg/ml. In comparison with other agents against coagulase-negative staphylococci (CNS), it showed 2- to 4-fold better potency (MIC90, 1µg/ml) than those of the comparative agents. Ceftaroline also demonstrated excellent activities against both community-associated methicillin-resistant S. aureus (MRSA) and hospital-acquired MRSA with MIC90s of 0.5 and 1µg/ml, respectively. All isolates of Streptococcus agalactiae, S. pneumoniae and Viridans streptococci were highly susceptible to ceftaroline (MIC90s, 0.06, 0.06 and 0.035µg/ml, respectively).
Conclusion: Ceftaroline demonstrated excellent in vitro activity against the majority of clinically significant isolates, except the non-fermenters, obtained from proven cases of bacterial infections,
H. Abdulkareem, None
A. Naji, None
F. Al-Failakawy, None